News Immunocore announces the presentation of initial data from the Phase 1 ImmTAV® trial for chronic Hepatitis B at the EASL International Liver Congress™ Staff June 25, 2022 Iframe sync Post navigation Previous: Jushi Holdings Inc. Amends and Refiles Q1 2022 Financial StatementsNext: Arbutus Presents New Data on AB-729, AB-836 and AB-101 at the EASL International Liver Congress™ 2022 and Provides AB-836 Clinical Update More Stories News TODAY SHOW EXPOSES AI MEDICAL SCAMS TARGETING LIPEDEMA PATIENTS Staff December 6, 2025 Healthcare News Pharmaceutical Queue Ventures Announces Closing of Brokered Private Placement of Subscription Receipts of Custom Fundco Inc. Staff December 5, 2025 Healthcare News Pharmaceutical Queue Ventures Announces Closing of Brokered Private Placement of Subscription Receipts of Custom Fundco Inc. Staff December 5, 2025
